Hu Xinyao, Zhu Hua, Chen Biao, He Xiaoqin, Shen Yang, Zhang Xiaoyu, Chen Wenliang, Liu Xin, Xu Yangtao, Xu Ximing
Cancer Center, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430060, China.
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430060, China.
Diagnostics (Basel). 2022 Mar 30;12(4):858. doi: 10.3390/diagnostics12040858.
Tubulin alpha 1b (TUBA1B) is an important microtubule isoform that is involved in the formation of the cytoskeleton. The objective of our study was to explore the potential of TUBA1B in predicting the prognosis of HCC and patients' response to immunotherapy. Raw data was extracted from TCGA and GEO databases, and then HCCDB, TIMER, HPA, and GEPIA websites, as well as R software, were used to perform bioinformatics analysis to investigate the potential of TUBA1B as a prognostic and immunotherapeutic marker for hepatocellular carcinoma (HCC). We found that both TUBA1B mRNA and protein were highly expressed in HCC. TUBA1B was proved to be an independent prognostic predictor of HCC. Additionally, TUBA1B expression was associated with the infiltration of several immune cells in HCC. Moreover, TUBA1B was coexpressed with immune-related genes and immune checkpoints. Patients expressing high TUBA1B responded better to immune checkpoint inhibitor (ICI) therapy. GO and KEGG analyses revealed that TUBA1B may be involved in the processes of cell cycle, spliceosome, and DNA replication. In conclusion, TUBA1B is expected to be a prognostic and immunotherapeutic marker for HCC.
微管蛋白α1b（TUBA1B）是一种重要的微管异构体，参与细胞骨架的形成。我们研究的目的是探讨TUBA1B在预测肝癌预后及患者对免疫治疗反应方面的潜力。从TCGA和GEO数据库中提取原始数据，然后利用HCCDB、TIMER、HPA和GEPIA网站以及R软件进行生物信息学分析，以研究TUBA1B作为肝细胞癌（HCC）预后和免疫治疗标志物的潜力。我们发现TUBA1B的mRNA和蛋白在肝癌中均高表达。TUBA1B被证明是肝癌独立的预后预测指标。此外，TUBA1B表达与肝癌中多种免疫细胞的浸润有关。而且，TUBA1B与免疫相关基因和免疫检查点共表达。高表达TUBA1B的患者对免疫检查点抑制剂（ICI）治疗反应更好。GO和KEGG分析显示，TUBA1B可能参与细胞周期、剪接体和DNA复制过程。总之，TUBA1B有望成为肝癌的预后和免疫治疗标志物。
